Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment

Mara Ten Kate1,2, Frederik Barkhof3,4, Pieter Jelle Visser5,6

  • 1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. m.tenkate1@vumc.nl.

Abstract

Insights

Predicting dementia progression in mild cognitive impairment (MCI) is crucial. This study found that reduced gray matter volume in specific brain regions, alongside amyloid pathology, predicts faster progression to dementia in MCI patients.

Area of Science:

  • Neuroscience
  • Radiology
  • Gerontology

Background:

  • Amyloid pathology is a key risk factor for Alzheimer's disease dementia in mild cognitive impairment (MCI).
  • Predicting dementia onset in MCI is challenging due to variable progression rates influenced by neurodegeneration.
  • Voxel-wise survival analysis offers an unbiased approach to assess MRI-based neurodegeneration and its link to dementia progression.

Purpose of the Study:

  • To identify brain regions with decreased gray matter volume that predict time to dementia in MCI using voxel-wise survival analysis.
  • To assess the influence of amyloid status on the association between gray matter volume and dementia progression.

Main Methods:

  • Included 276 MCI subjects with baseline MRI, CSF biomarkers, and clinical follow-up.
  • Applied voxel-wise proportional Cox hazards regression to structural MRI data.
  • Stratified analyses by baseline amyloid status to evaluate its effect on dementia progression.

Main Results:

  • 44% of subjects progressed to dementia within an average follow-up of 2.5 years.
  • Amyloid positivity significantly increased dementia risk (HR 2.4, p < 0.001).
  • Decreased gray matter volume in widespread regions (hippocampal, temporal, parietal, frontal) correlated with faster dementia progression in both amyloid-positive and amyloid-negative MCI subjects.

Conclusions:

  • Both abnormal amyloid levels and reduced gray matter volume are associated with future dementia in MCI.
  • The pattern of gray matter loss predicting dementia progression is consistent regardless of amyloid status in MCI.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
597
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.1K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K